Soligenix boosts at-the-market stock capacity
Soligenix, Inc. increased by $2,500,000 the maximum aggregate amount of its common stock that may be issued under its at-the-market sales agreement with Rodman & Renshaw LLC, through a new prospectus supplement.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Soligenix, Inc. increased by $2,500,000 the maximum aggregate amount of its common stock that may be issued under its at-the-market sales agreement with Rodman & Renshaw LLC, through a new prospectus supplement. The company previously sold about $6,234,000 of common stock under earlier supplements that covered up to $6,406,000 of shares. The 8-K also files the related legal opinion from Duane Morris LLP as an exhibit.
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Additional ATM capacity: $2,500,000 common stock
Previously sold under ATM: $6,234,000 common stock
Prior ATM coverage limit: $6,406,000 common stock
3 metrics
Additional ATM capacity
$2,500,000 common stock
Increase in maximum aggregate offering amount under sales agreement
Previously sold under ATM
$6,234,000 common stock
Shares sold pursuant to prior prospectus supplements
Prior ATM coverage limit
$6,406,000 common stock
Aggregate amount of shares covered by earlier supplements
Key Terms
prospectus supplement, At Market Issuance Sales Agreement, emerging growth company, legal opinion, +1 more
5 terms
prospectus supplement regulatory
"filed a prospectus supplement (the “Current Prospectus Supplement”) to increase the maximum aggregate offering"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
At Market Issuance Sales Agreement financial
"issuable under the At Market Issuance Sales Agreement, dated January 23, 2026"
An at market issuance sales agreement is a setup where a company arranges for an agent to sell newly issued shares directly into the public market at the current trading price, usually over time as needed. It matters to investors because it gives the company quick, flexible access to cash without setting a fixed price, but can dilute existing shareholders and affect the stock’s supply and short‑term price behavior—like a shop owner adding extra items to a shelf and selling them at whatever the going price is.
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
legal opinion regulatory
"A copy of the legal opinion as to the legality of the $2,500,000 of shares of common stock"
Other Events regulatory
"Item 8.01 Other Events. On June 26, 2026, Soligenix, Inc."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Soligenix (SNGX) change in its at-the-market offering?
Soligenix increased the maximum aggregate amount of common stock issuable under its at-the-market sales agreement by $2,500,000, using a new prospectus supplement. This expands the capacity of shares that can be sold into the market over time.
How much stock has Soligenix (SNGX) already sold under the sales agreement?
Soligenix previously sold approximately $6,234,000 of common stock under the at-the-market sales agreement. Those sales were made pursuant to earlier prospectus supplements that together covered up to $6,406,000 of shares.
Who is Soligenix’s sales agent under the at-the-market program?
Rodman & Renshaw LLC is the sales agent under Soligenix’s At Market Issuance Sales Agreement dated January 23, 2026. The agreement allows Soligenix to issue and sell common stock from time to time through the agent.
What legal documents did Soligenix (SNGX) file with this 8-K?
Soligenix filed an opinion of Duane Morris LLP as Exhibit 5.1 and a related consent as Exhibit 23.1. The legal opinion addresses the legality of the additional $2,500,000 of common stock covered by the current prospectus supplement.
What type of event is described in this Soligenix (SNGX) 8-K?
The 8-K reports an Item 8.01 Other Events disclosure. It explains that Soligenix filed a prospectus supplement to increase the capacity of its at-the-market common stock offering and includes the associated legal opinion exhibits.
AI-generated analysis. How Rhea-AI works. Not financial advice.
